The DEA's April 2026 final order moved state-licensed medical marijuana and FDA-approved marijuana products to Schedule III, while adult-use cannabis remained Schedule I. A subsequent administrative hearing on broader rescheduling from Schedule I to III ran from June 29 to July 15, 2026, with the DEA presenting evidence of accepted medical use drawn from the prior HHS scientific review. Closing briefs were filed in August, and the full transcript was released shortly after. On September 9, 2026, the D.C. Circuit rejected challenges seeking to stay the April order. Chief Administrative Law Judge Derek Julius is now preparing a recommendation for the DEA Administrator, whose final decision will determine the scope and timing of any further change. Ongoing litigation and the outcome of that recommendation remain the primary variables for market resolution.
基於Polymarket數據的AI實驗性摘要。這不是交易建議，也不影響該市場的結算方式。 · 更新於$809,956 交易量
2026-09-30
9月30日
3%
12月31日
16%
$809,956 交易量
9月30日
$679 交易量
3%
12月31日
$199,706 交易量
16%
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.The DEA's April 2026 final order moved state-licensed medical marijuana and FDA-approved marijuana products to Schedule III, while adult-use cannabis remained Schedule I. A subsequent administrative hearing on broader rescheduling from Schedule I to III ran from June 29 to July 15, 2026, with the DEA presenting evidence of accepted medical use drawn from the prior HHS scientific review. Closing briefs were filed in August, and the full transcript was released shortly after. On September 9, 2026, the D.C. Circuit rejected challenges seeking to stay the April order. Chief Administrative Law Judge Derek Julius is now preparing a recommendation for the DEA Administrator, whose final decision will determine the scope and timing of any further change. Ongoing litigation and the outcome of that recommendation remain the primary variables for market resolution.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
市場開放時間： Jul 31, 2026, 5:46 PM ET
交易量
$809,956結束日期
2027-01-01市場開放時間
Jul 31, 2026, 5:46 PM ETThis market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.The DEA's April 2026 final order moved state-licensed medical marijuana and FDA-approved marijuana products to Schedule III, while adult-use cannabis remained Schedule I. A subsequent administrative hearing on broader rescheduling from Schedule I to III ran from June 29 to July 15, 2026, with the DEA presenting evidence of accepted medical use drawn from the prior HHS scientific review. Closing briefs were filed in August, and the full transcript was released shortly after. On September 9, 2026, the D.C. Circuit rejected challenges seeking to stay the April order. Chief Administrative Law Judge Derek Julius is now preparing a recommendation for the DEA Administrator, whose final decision will determine the scope and timing of any further change. Ongoing litigation and the outcome of that recommendation remain the primary variables for market resolution.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
交易量
$809,956結束日期
2027-01-01市場開放時間
Jul 31, 2026, 5:46 PM ETThe DEA's April 2026 final order moved state-licensed medical marijuana and FDA-approved marijuana products to Schedule III, while adult-use cannabis remained Schedule I. A subsequent administrative hearing on broader rescheduling from Schedule I to III ran from June 29 to July 15, 2026, with the DEA presenting evidence of accepted medical use drawn from the prior HHS scientific review. Closing briefs were filed in August, and the full transcript was released shortly after. On September 9, 2026, the D.C. Circuit rejected challenges seeking to stay the April order. Chief Administrative Law Judge Derek Julius is now preparing a recommendation for the DEA Administrator, whose final decision will determine the scope and timing of any further change. Ongoing litigation and the outcome of that recommendation remain the primary variables for market resolution.
基於Polymarket數據的AI實驗性摘要。這不是交易建議，也不影響該市場的結算方式。 · 更新於
警惕外部連結哦。
警惕外部連結哦。
Frequently Asked Questions